5820 Nancy Ridge Dr.
About Vividion Therapeutics
Vividion Therapeutics is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide ligand and target discovery. Headquartered in San Diego, CA, Vividion Therapeutics is a private, biotechnology company founded in 2014 with seed financing from Cardinal Partners as a spin out from the labs of Dr. Benjamin Cravatt, Dr. Phil Baran and Dr. Jin-Quan Yu at TSRI. In 2017, Vividion launched with $50 million in Series A financing from ARCH Venture Partners, Versant Ventures and founding investor Cardinal Partners
* Benjamin F. Cravatt III, Ph.D., Professor and Co-Chair, Department of Molecular Medicine, the Skaggs Institute for Chemical Biology at The Scripps Research Institute
* Phil S. Baran, Ph.D., Professor, Darlene Shiley Professor of Chemistry, Department of Chemistry, the Skaggs Institute for Chemical Biology at The Scripps Research Institute
* Jin-Quan Yu, Ph.D., Frank and Bertha Hupp Professor of Chemistry, Department of Chemistry, The Scripps Research Institute
* John K. Clarke, Managing General Partner, Cardinal Partners
Please click here for Vividion's job opportunities.
10 articles with Vividion Therapeutics
Every year, Forbes creates a list of 30 Under 30, people under the age of 30 who have made a mark and show promise in various areas. They just came out with the 2019 30 Under 30: Healthcare. Here we highlight a dozen of the winners for their roles in biopharma-related endeavors.
10/1/2018Here's a look at who shook things up in the world of pharma and biotech this week.
Vividion Therapeutics Expands Leadership Team with the Appointments of Fred Aslan, M.D., President and Chief Business Officer, and Larry Burgess, Ph.D., Head of Chemistry
Vividion Therapeutics today announced the appointments of Fred Aslan, M.D. as President and Chief Business Officer and Larry Burgess, Ph.D. as Head of Chemistry.
Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for multiple sclerosis treatment ozanimod.
Scott Smith, Celgene’s chief operating officer, abruptly resigned Monday. His decision to leave appears to be prompted by a restructuring of the company’s executive team.
Prothena Therapeutics has forged a collaboration with Celgene worth a potential $2B to develop new therapies for a broad range of neurodegenerative diseases.
Celgene handed over $101 million in upfront monies to San Diego-based Vividion Therapeutics, Inc. as part of an agreement to develop small molecule therapies.
Vividion Therapeutics Announces Strategic Research Collaboration with Celgene Corporation to Discover Therapies Against Transformative, First-in-Class Targets
Vividion Therapeutics, Inc. announced a strategic research collaboration with Celgene Corporation.